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Abstract
Background: Plasma β-amyloid (Aβ) is a potential candidate for an Alzheimer’s disease (AD) biomarker because blood is
an easily accessible bio-fluid, which can be collected routinely, and Aβ is one of the major hallmarks of AD pathogenesis
in the brain. However, the association between plasma Aβ levels and AD diagnosis is still unclear due to the instability
and inaccurate measurements of plasma Aβ levels in the blood of patients with AD. If a consistent value of plasma Aβ
from the blood can be obtained, this might help determine whether plasma Aβ is a potential biomarker for AD diagnosis.
Methods: We predicted the brain amyloid deposit by measuring the plasma Aβ levels. This cross-sectional study included
353 participants (215 cognitively normal, 79 with mild cognitive impairment, and 59 with AD dementia) who underwent
Pittsburgh-compound B positron emission tomography (PiB-PET) scans. We treated a mixture of protease inhibitors and
phosphatase inhibitors (MPP) and detected plasma Aβ42 and Aβ40 (MPP-Aβ42 and MPP-Aβ40) in a stable
manner using xMAP technology.
Results: MPP-Aβ40 and MPP-Aβ42/40 (MPP-Aβs) were significantly different between subjects with positive amyloid
deposition (PiB+) and those with negative amyloid deposition (PiB–) (P < 0.0001). Furthermore, MPP-Aβ40 (P < 0.0001,
r = 0.23) and MPP-Aβ42/40 ratio (P < 0.0001, r = –0.23) showed significant correlation with global PiB deposition
(standardized uptake value ratio). In addition, our integrated multivariable (MPP-Aβ42/40, gender, age, and
apolipoprotein E genotypes) logistic regression model proposes a new standard for the prediction of cerebral amyloid
deposition.
Conclusions: MPP-Aβ might be one of the potential blood biomarkers for the prediction of PiB-PET positivity in the brain.
Keywords: Alzheimer’s disease, β-amyloid, Plasma Aβ, Blood-based biomarker, MPP, Pittsburgh-compound B positron
emission tomography
Background
Alzheimer’s disease (AD) is the most common cause of
dementia usually observed in populations over the age
of 65 years and is characterized by β-amyloid (Aβ)
plaques and neurofibrillary tangles in the brain [1, 2].
The insoluble aggregates of Aβ peptides are associated
with cognitive impairment, synapse loss, and neuronal
cell death, and this may precede the onset of dementia
[3, 4]. In addition, there is no currently available cure for
AD, and current drugs only alleviate the symptoms of
dementia but do not cure the underlying disease [5].
Abnormal aggregation of Aβ is the earliest pathological
event in AD, and existing drugs only slow down AD
progression. Hence, the diagnosis of AD at the early
stages of the disease is the most promising method for
effective follow-up measures, although it is very challen-
ging. Furthermore, although AD has no known cure,
early detection of the disease is promising because the
devastating disease can be prevented through well-
known methods for reducing risk factors such as doing
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some exercises, healthy diet, controlling blood pressure,
having strong social support, taking folic acid supple-
ments, and not smoking [6–11].
Efforts to identify the available and effective bio-
markers for AD have been made in many countries. In
the neuroimaging field, specific regional brain atrophy
can be observed by magnetic resonance imaging (MRI),
and Aβ deposition in the brain can be detected by posi-
tron emission tomography (PET) using specific radio-
active ligands including Pittsburgh compound B (PiB)
[12]. However, these are costly procedures for AD
diagnosis [13]. Additionally, although molecular bio-
markers such as tau and Aβ can be measured in the
cerebrospinal fluid (CSF) [14], the collection of CSF is a
highly invasive procedure [15].
On the other hand, the blood is an easily accessible
bio-fluid which can be routinely collected and analyzed
to detect or track the disease [15]. Hence, if we utilize
blood proteins as a biomarker for AD, this might help
recognize the disease earlier because of the simple
method and high frequency of blood collection. Several
studies reported the efflux/influx of Aβ across the
blood–brain barrier and identified various Aβ trans-
porters; hence, many researchers believe that plasma Aβ
might reflect brain amyloid deposition [16]. However,
the association between plasma Aβ levels and AD diag-
nosis is still unclear. Several cross-sectional studies
showed that low plasma Aβ42 levels or Aβ42/40 ratios
are associated with AD [17, 18]. Some prospective
studies have also suggested that a decrease in plasma
Aβ42/40 ratio is related to cognitive impairment [19, 20].
However, these results are in contrast with other reports,
which indicate an increase in Aβ42 with cognitive decline
[21], no association between plasma Aβ levels and AD [22],
and a relation between low plasma Aβ40 and AD [23].
Thus, evidence for the effectiveness of measurement of
plasma Aβ42, Aβ40, and the Aβ42/40 ratios in the diagno-
sis of AD is lacking. Such controversy on the relationship
between plasma Aβ levels and AD may result from the in-
accuracy in both plasma Aβ measurement and AD clinical
diagnosis. In addition, plasma Aβ levels show unpredictable
fluctuations in their values because of numerous factors.
Human serum albumin (HSA) and transthyretin (TTR)
interrupt the detection of Aβ [24–27] because both of them
bind to Aβ, and their interaction status varies depending on
blood dynamics [28, 29]. Furthermore, protease inhibitors
and phosphatase inhibitors in the blood might play a role
in decreasing Aβ degradation because the Aβ sequence
contains many possible proteases and phosphorylation sites
[30, 31]. After blood collection, both protease inhibitors
and phosphatase inhibitors are randomly activated, which
affects Aβ degradation and the interaction between Aβ and
other proteins in the blood [31, 32], resulting in the fluctu-
ation of the measurable Aβ concentration in the blood.
Moreover, about 12% of patients with clinically diag-
nosed AD dementia (ADD) do not exhibit AD path-
ology, and 23% of cognitively normal (CN) individuals
show AD pathology [3, 33]. Hence, the blood samples
from previous studies that did not have PiB-PET data
for the participants were not homogeneous samples in
the view of brain amyloid pathology, which might have
yielded the conflicting results for plasma Aβ level.
In this study, we aimed to investigate the potential of
plasma Aβ level as a diagnostic or screening marker for
AD. To resolve the instability or inaccuracy in assess-
ment, we applied two distinct approaches. First, all
participants underwent PiB-PET to quantify the cerebral
Aβ deposition. This approach allowed us to test the
effectiveness of plasma Aβ as a biomarker using patho-
logical AD diagnosis, instead of clinical AD diagnosis, as
the gold standard. Second, we developed a novel mixture
(MPP, a mixture of protease inhibitors and phosphatase
inhibitors) and treated the plasma with MPP to detect
plasma Aβ levels in a stable and accurate manner using
xMAP technology. Under this new but simple method,
we determined that MPP-Aβ might be a reliable blood
biomarker for screening cerebral amyloid deposition.
Methods
This study was part of the Korean Brain Aging Study
for Early Diagnosis and Prediction of Alzheimer’s
Disease (KBASE), an ongoing prospective cohort
study aimed at searching for new biomarkers for AD
and elucidating various life experiences contributing
to AD-related brain changes. This work was approved
by the Institutional Review Board (IRB) of the Seoul
National University Hospital, South Korea, and the
subjects or their legal representatives provided their
written informed consent. Additional file 1 shows the
experimental flow chart for this study.
Participants
Overall 353 middle-aged or old-aged subjects with
age ≥ 55 years, including 215 CN individuals, 79 indi-
viduals with mild cognitive impairment (MCI), and 59
individuals with ADD, participated in the study. All partici-
pants underwent comprehensive clinical and neuropsycho-
logical assessments, neuroimaging examinations including
structural MRI and PiB-PET, and comprehensive laboratory
blood tests. CN participants had a Clinical Dementia Rating
(CDR) score of 0 [34] and were without diagnoses of MCI
or dementia. Individuals with MCI met the following
criteria: (a) memory complaint corroborated by self, an
informant, or a clinician; (b) objective memory impairment
for age, education, and gender; (c) largely intact functional
activities; and (d) not demented. All individuals with MCI
had a global CDR score of 0.5. In terms of criterion (b), all
participants with MCI had a performance score at least 1.5
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standard deviation (SD) below the respective age-specific,
education-specific, and gender-specific mean for at least
one of the four episodic memory tests included in the
Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) neuropsychological battery (namely, Word List
Memory, Word List Recall, Word List Recognition, and
Constructional Recall test) [35]. Patients with ADD met
both the criteria for dementia (in accordance with the
Diagnostic and Statistical Manual, fourth edition (DSM-
IV)) [36] and the criteria for probable AD set in accordance
with the National Institute of Aging and Alzheimer’s
Association (NIA-AA) guidelines [37]. The exclusion
criteria for all participants were: any present serious
medical, psychiatric, and neurological disorders that
could affect mental function; the presence of severe
communication problems that would make a clinical
examination or brain scan difficult; contraindications
for MRI scan (e.g., pacemaker, claustrophobia); absence of a
reliable informant; and illiteracy.
Clinical and neuropsychological assessment
Participants were administered standardized clinical assess-
ments based on the KBASE clinical assessment protocol,
which incorporated the Korean version of the Consortium
to Establish a Registry for Alzheimer’s Disease Assessment
Packet (CERAD-K) [38], by trained psychiatrists. They were
also administered the KBASE neuropsychological assess-
ment protocol incorporating the CERAD neuropsycho-
logical battery [35], which included the Mini-Mental State
Examination (MMSE), by trained neuropsychologists. In
this study we used the MMSE z score, with consideration
for age, gender, and education levels, because the basic
demographic information of subjects such as gender, age,
and education is known to have an effect on the change in
MMSE scores [39].
Blood sampling
Blood samples were obtained via venipuncture in the
morning (around 9:00 am) after an overnight fast and
collected several hours before the injection of PET tracer
in K2 ethylenediaminetetraacetic acid (EDTA) tubes (BD
Vacutainer Systems, Plymouth, UK). The samples were
stabilized and centrifuged at 700 × g for 5 min at room
temperature (RT) to obtain the plasma supernatants in
15-ml centrifuge tubes (SPL Life Sciences Co.,
Gyeonggi-do, Korea). To obtain the samples with high
purity, the plasma supernatants were further centrifuged
under the same conditions, and the collected pure
plasma supernatants were aliquoted and stored immedi-
ately at –80 °C.
PiB-PET
Participants underwent simultaneous three-dimensional
PiB-PET imaging and T1-weighted MR using a Biograph
mMR scanner (Siemens, Washington, DC, USA) with the
manufacturer’s approved guidelines. A 30-min emission
scan was acquired after 40 min of intravenous administra-
tion of 555 MBq of 11C-PiB (range, 450–610 MBq). The
PiB-PET data collected in the list mode were processed for
routine corrections such as uniformity, ultrashort echo time
(UTE)-based attenuation, and decay corrections and were
reconstructed into a 256 × 256 image matrix using iterative
methods (six iterations with 21 subsets). T1-weighted scans
(repetition time = 1670 ms; echo time = 1.89 ms; field of
view = 250 mm; 256 × 256 matrix with 1.0 mm slice
thickness) were acquired in the sagittal orientation. The fol-
lowing image preprocessing steps were performed using
Statistical Parametric Mapping 8 (SPM8) implemented in
MATLAB 2014a (MathWorks, Natick, MA, USA).
Static PiB-PET images were coregistered to the indi-
vidual T1 structural images and transformation
parameters for spatial normalization of the individual
T1 images to a standard Montreal Neurological Institute
(MNI) template were calculated. Utilizing Individual Brain
Atlases using Statistical Parametric Mapping Software
(IBASPM) software, the inverse transformation parameters
were used to transform the coordinates from the automatic
anatomic labeling (AAL) 116 atlas [40] into an individual
space for each subject (resampling voxel size = 1 × 0.98 ×
0.98 mm3). The nongray matter portions of the atlas were
individually masked using the cerebral gray matter segment
image from each subject.
The mean regional 11C-PiB uptake values from the
cerebral regions were extracted using the individual
AAL116 atlas from the T1-coregistered PiB-PET images.
The cerebellar gray matter was used as the reference
region due to its relatively low Aβ deposition for the
quantitative normalization of cerebral 11C-PiB uptake
values. To measure the 11C-PiB uptake in the cerebellar
gray matter regions, a probabilistic cerebellar atlas (Institute
of Cognitive Neuroscience, UCL; Cognitive Neuroscience
Laboratory, Royal Holloway) was transformed into an indi-
vidual space in the same manner as already described. Of
the 28 anatomical structural regions in the cerebellar atlas,
all of the cerebellar lobular regions except for the vermis
were included to extract the mean cerebellar uptake values.
The AAL algorithm and a region-combining method [20]
were applied to determine the regions of interest (ROIs) to
characterize the 11C-PiB retention level in the frontal,
lateral parietal, posterior cingulate-precuneus (PC-PRC),
and lateral temporal regions, where prominent 11C-PiB
retention has been reported [13].
The standardized uptake value ratio (SUVR) values for
each ROI were calculated by dividing the mean value for
all voxels within each ROI by the mean cerebellar uptake
value in the same image. Each participant was classified
as PiB-positive (PiB+) if the SUVR value was >1.4 in at
least one of the four ROIs (i.e., frontal, lateral temporal,
Park et al. Alzheimer's Research & Therapy  (2017) 9:20 Page 3 of 13
lateral parietal, and PC-PRC) or PiB-negative (PiB–) if
the SUVR values of all four ROIs were ≤1.4 [17]. A
global cortical ROI consisting of the four ROIs was also
defined, and a global PiB deposition value (SUVR) was
generated by dividing the mean value for all voxels of
the global cortical ROI by the mean cerebellar uptake
value of the same image.
Reagents
The mixture of protease inhibitors and phosphatase
inhibitors (MPP) was composed of protease inhibitor
cocktail (PI), phenylmethanesulfonyl fluoride (PMSF, a
serine protease inhibitor; Sigma-Aldrich, CA, USA), and
phosphatase inhibitor cocktail I and II (PPI I and II; A.
G. Scientific, Inc., CA, USA). They were mixed in the
same proportion. Aβ peptide was purchased from
Bachem Americas, Inc. (Torrance, CA, USA) and
prepared as described previously [41]. HSA (Sigma-Aldrich)
was used for mimicking the plasma sample condition
because it is the most abundant protein in the human
plasma [25, 42, 43].
INNO-BIA plasma Aβ forms assay using xMAP technology
To simultaneously determine the concentrations of
plasma Aβ42 and Aβ40, the INNO-BIA plasma Aβ
forms kit (Innogenetics, Gent, Belgium) was used in
accordance with the manufacturer’s guidelines. In brief,
the samples were diluted 3-fold in the MPP-treated
plasma diluent buffer (final concentration, 4% MPP solu-
tion in plasma diluent buffer) or MPP nontreated plasma
diluent buffer and incubated for 30 min at RT. After
washing the filter plate, the diluted bead mix was trans-
ferred to the wells of the plate. The plate was dried
gently, washed, and 25 μl of conjugate 1 working solu-
tion A and 75 μl of standards, blanks, controls, and
diluted plasma samples were added. The plate was in-
cubated overnight at 4 °C, and the next day each well
was washed with 100 μl of the detection solution
added to the mixture. After 1 h, the plates were
washed again, and the reading solution was added to
each well. The levels of plasma Aβ were measured
using xMAP technology (Bioplex 200 systems;
Bio-Rad, Hercules, CA, USA).
Proof-of-concept experiments
Gel electrophoresis
We prepared the synthetic Aβ42 (diluted in 1× phos-
phate buffered saline (PBS), 2 μM) to visualize the
change in Aβ form against MPP treatment. Aβ42
solution was equally divided (20 μl) among eight 1.5 ml
tubes. For repetitive measurement assay without plasma
(pure synthetic Aβ42), 20 μl of 8% dimethyl sulfoxide
(DMSO) in 1× PBS (–MPP) (n = 4; Fig. 2a, lanes 1–4) or
8% MPP solution in 1× PBS (+MPP) (n = 4; Fig. 2a, lanes
5–8) was added to the Aβ42 solution (final concentra-
tion: 1 μM of Aβ42). For repetitive measurement assay
with the original plasma sample, 20 μl of 8% DMSO and
25% plasma in 1× PBS (–MPP) (n = 4; Fig. 2b, lanes 1–4)
or 8% MPP solution and 25% plasma in 1× PBS (+MPP)
(n = 4; Fig. 2b, lanes 5–8) was added to the Aβ42 solu-
tion (final concentration: 1 μM of Aβ42). The samples
were incubated for 30 min at RT and then mixed with
4× sample buffer (without boiling) and loaded equally on
4–12% NuPAGE bis-tris gel (Thermo Fisher Scientific,
Waltham, MA, USA) for gel electrophoresis. Next, the gel
was transferred to a polyvinylidene difluoride (PVDF)
membrane for 60 min at 70 V, and the membrane was
blocked with 5% skim milk in 1× Tris buffered saline with
Tween 20 (TBST) for 1 h. After blocking, the mem-
brane was incubated with anti-6E10 Aβ antibody (pri-
mary antibodies overnight at 4 °C) and the following
day with secondary antibodies for 1 h at RT. The
protein bands on the PVDF membrane were visual-
ized using a bio-imaging analyzer (LAS-3000; Fujifilm
Corporation, Tokyo, Japan) with a chemiluminescence
detection solution (Ab Frontier Co., Seoul, Korea).
The images were imported from a Multi-Gauge pro-
gram (Fujifilm Corporation), and the band intensities
(ratio, %) were measured (monomeric Aβ, ~4 kDa;
oligomeric Aβ, 8–14 kDa) [44].
xMAP technology
We repetitively measured the synthetic Aβ and plasma Aβ
levels using xMAP technology. For synthetic Aβ levels, 4%
MPP solution (or absent), 0.5% HSA (or absent), and Aβ42
(200 pg/ml) (aliquots from the same pool, in separate
1.5-ml tubes; –MPP or +MPP, each n = 6) in Bioplex
sample diluent buffer were incubated for 30 min at RT,
followed by Aβ42 measurement using xMAP technology.
For plasma Aβ levels, samples (aliquots from the same
pooled plasma, in separate 1.5-ml tubes, n = 5) were diluted
3-fold in MPP-treated plasma diluent buffer (final concen-
tration, 4% MPP solution in plasma diluent buffer) or
MPP nontreated plasma diluent buffer, incubated for
30 min at RT, and then measured using xMAP tech-
nology (–MPP or +MPP, each n = 5).
Time-dependent alterations in plasma Aβ42 and Aβ40
levels
Plasma Aβ42 and Aβ40 levels were quantified in a time-
dependent manner using xMAP technology. We used
individual human plasma samples (n = 4) and also
diluted them 3-fold in MPP-treated plasma diluent buf-
fer (final concentration, 4% MPP solution in plasma
diluent buffer) or MPP nontreated plasma diluent
buffer, and incubated at RT followed by measurement
at each time point (0, 6, 12, 24 h) and quantification
(–MPP or +MPP, each n = 4).
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Effects of MPP on discrimination between subject groups
Plasma samples (20 CN–, 12 MCI+, 23 ADD+, total of
55 subjects; – and +, PiB-PET positivity) were diluted
3-fold in MPP-treated plasma diluent buffer (final con-
centration, 4% MPP solution in plasma diluent buffer) or
MPP nontreated plasma diluent buffer and incubated for
30 min at RT followed by measurement using xMAP
technology. We compared the intergroup differences in
MPP-treated plasma Aβ (MPP-Aβ) with those of non-
MPP-treated plasma Aβ (nMPP-Aβ).
Statistics
Statistical analysis was performed using GraphPad Prism
5 (GraphPad Software, San Diego, CA, USA) and
Medcalc (Medcalc Software, Ostend, Belgium). All data
are presented as mean ± standard error of mean (SEM).
An unpaired t test was used to assess the quantitative
differences between two groups. For the tests of differ-
ences between three groups or more, multifactorial
analyses of variance (ANOVA) followed by Tukey’s mul-
tiple comparisons tests were performed. We used a
bivariate correlation analysis to test the association be-
tween variables. Furthermore, we conducted logistic
regression analysis followed by receiver operating char-
acteristic (ROC) curve analysis on these values using
Medcalc software. Cutoff criteria (optimal cutoff point)
were determined by the Youden index [45] with an
appropriate balance between sensitivity and specificity.
Pearson’s chi-square test (χ2) was carried out to evaluate
the intergroup differences of two-category variables
(gender, apolipoprotein E ε4 carrier status) using Medcalc
software. To compare the variance between –MPP
and +MPP in the repetitive measurement assay, an F
test was performed (GraphPad Prism 5). Squared deviation
((value –mean value)2) indicates how far each point is from
the mean value. Because the y axis of the graphs indicates
the squared deviation in Fig. 2a–d, the highest points of




where X is an individual data point, m is the mean of
data points, and N is the total number of data points.
Statistically significant results were shown as the appro-
priate P value.
Results
Demographic data of subjects
A total of 353 subjects were included in this study.
Subjects were classified according to their pathological
(brain Aβ deposition) and/or clinical diagnosis (Fig. 1,
Table 1, and Additional file 2). Two hundred and fifty-
three subjects with negative amyloid deposition (PiB–)
and 100 subjects with positive amyloid deposition (PiB+)
were included; out of which 187 were PiB– CN (CN–),
50 were PiB– MCI (MCI–), 16 were PiB– ADD (ADD–),
28 were PiB+ CN (CN+), 29 were PiB+ MCI (MCI+),
and 43 were PiB+ ADD (ADD+). Figure 1b shows the
representative PiB-PET images of the study cohort
(n = 353). The colors of the rainbow spectrum show
the degree of Aβ deposition (PiB retention, SUVR;
red→ purple, high→ low, respectively).
Proof-of-concept experiments for the effects of MPP on
Aβ quantification
To verify the effect of MPP on Aβ quantification, we used
the synthetic Aβ42 and plasma samples for the proof-of-
concept experiments (POC) (Fig. 2). When the same con-
centration of synthetic Aβ42 (final concentration: 1 μM of
Aβ42) in the presence or absence of MPP was electropho-
resed using western blotting, the Aβ42 samples without
Fig. 1 Categorized subject groups. a Classification of subjects (n= 353)
for the study. b Representative PiB-PET images of the study
cohort (n = 353). Participants were classified as PiB-positive (PiB+) if the
PiB retention (SUVR) value was >1.4 in at least one of the four ROIs (i.e.,
frontal, lateral temporal, lateral parietal, and PC-PRC) or PiB-negative
(PiB–) if the SUVR values of all four ROIs were ≤1.4. – or + PiB-PET
positivity, CN cognitively normal, MCI mild cognitive impairment, ADD
Alzheimer’s disease dementia, ND nondemented, PiB-PET
Pittsburgh-compound B positron emission tomography, SUVR
standard uptake value ratio (Color figure online)
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MPP treatment showed variable band intensities among all
four lanes of the blot, whereas MPP-treated Aβ42 samples
presented consistent band intensities in the blot (Fig. 2a; P
< 0.01, F test; for monomeric Aβ, variance decreased by
34.75%2; for oligomeric Aβ, variance decreased by 16.11%2).
Similarly, this phenomenon occurred when the original
plasma sample was added (Fig. 2b; P < 0.1 and P < 0.01, F
test; for monomeric Aβ, variance decreased by 3.16%2; for
oligomeric Aβ, variance decreased by 1.86%2). Next, we
treated synthetic Aβ42 with MPP and/or HSA and mea-
sured the Aβ42 level using xMAP technology. Interestingly,
the repetitively measured Aβ42 concentrations showed dra-
matically reduced variance among their values for the
MPP-treated sample set (Fig. 2c; P < 0.001, without HSA,
variance decreased by 1190.6 pg2/ml2; P < 0.01 with HSA,
variance decreased by 70.99 pg2/ml2; F test). Furthermore,
the repetitive measurement of plasma Aβ42 and Aβ40
showed significantly reduced variation (Fig. 2d; plasma
Aβ42, P < 0.05, variance decreased by 22.70 pg2/ml2; plasma
Aβ40, P < 0.01, variance decreased by 1151.34 pg2/ml2; F
test). In addition, we identified whether MPP could inhibit
the degradation of plasma Aβ over time (from 0 to 24 h)
because a previous study reported that plasma sample
storage at RT leads to a significant loss of measurable Aβ
peptide level [46]. For the human plasma samples, MPP-
treated plasma Aβ42 (MPP-Aβ42) and MPP-Aβ40
remained stable for 24 h whereas non-MPP-treated plasma
Aβ42 (nMPP-Aβ42) levels decreased rapidly, and nMPP-
Aβ40 levels fluctuated (Fig. 2e, P < 0.05, unpaired t test at
each time point). This result indicates that MPP has an
effect on stabilizing plasma Aβ for 24 h.
POC for the effects of MPP on the distinction among the
subject groups
To examine the correlation between the plasma Aβ con-
centration and brain Aβ deposition, plasma samples
from 55 subjects (20 CN–, 12 MCI+, 23 ADD+; see
Additional file 4 for more detail) who received PiB-PET
imaging were used for further analysis (Fig. 3a, b).
nMPP-Aβ42 and nMPP-Aβ42/40 levels showed no
significant intergroup differences among all groups. In
contrast, MPP-Aβ42 and MPP-Aβ42/40 were signifi-
cantly lower in MCI+ subjects (MPP-Aβ42, 39.76 ±
3.26 pg/ml; MPP-Aβ42/40, 0.24 ± 0.02) and ADD+ subjects
(MPP-Aβ42, 38.65 ± 2.45 pg/ml; MPP-Aβ42/40, 0.25 ±
0.02) compared with CN– subjects (MPP-Aβ42, 56.98 ±
3.57 pg/ml; MPP-Aβ42/40, 0.34 ± 0.02) (Fig. 3a; P < 0.01
and P < 0.001, ANOVA followed by Tukey’s multiple
comparison test). Interestingly, when global PiB deposition
values (SUVR) were plotted with plasma Aβ concen-
tration, MPP-Aβ42 and MPP-Aβ42/40 (Fig. 3b; MPP-Aβ42,
P < 0.001, r =–0.47; MPP-Aβ42/40, P < 0.01, r =–0.39;
Pearson’s correlation) were more correlated with brain
amyloid deposit than nMPP-Aβ42 and nMPP-Aβ42/40
(Fig. 3b; nMPP-Aβ42, P < 0.05, r =–0.29; nMPP-Aβ42/40,
P = 0.12, r =–0.21; Pearson’s correlation). Therefore, we
suggest that the treatment of the plasma with MPP
provides an improved detection method for stable and reli-
able plasma Aβ level, and plasma Aβ concentration might
reflect the brain amyloid deposit.
MPP-Aβs reflect the pathological load of Aβ in the brain
In the POC, we demonstrated that MPP works effi-
ciently to improve stability in the quantification of
plasma Aβ. To examine further the association of MPP-
Aβ levels with the progression of AD, we conducted the
main experiments by increasing the number of subjects
(overall 353 subjects: 187 CN–, 50 MCI–, 16 ADD–, 28
CN+, 29 MCI+, and 43 ADD+; Fig. 4). Likewise with
POC results, CN– subjects had higher MPP-Aβ42
(44.57 ± 1.05 pg/ml) concentration than ADD+ subjects
(37.50 ± 1.72 pg/ml) (P < 0.05, Fig. 4a, left graph;
Table 1 Demographic data of the complete study cohort for the main experiments (PiB– vs PiB+)
Group (total, n = 353)
Basic characteristic PiB– (n = 253) PiB+ (n = 100) P valuea
Global PiB deposition, mean ± SEM 1.11 ± 0.004 1.91 ± 0.038 <0.001
Clinical diagnosis, N/M/D 187/50/16 28/29/43 <0.001†
Gender, male/female 95/158 38/62 >0.05†
Age (years), mean ± SEM 69.94 ± 0.5 73.00 ± 0.7 <0.001
CDR, mean ± SEM 0.15 ± 0.02 0.5 ± 0.04 <0.001
MMSE z score,b mean ± SEM –0.13 ± 0.07 –1.91 ± 0.20 <0.001
Education, mean ± SEM 10.65 ± 0.3 10.82 ± 0.5 >0.05
ApoE4-positive, n/N (%) 39/253 (15%) 57/100 (57%) <0.001†
Details of clinical diagnosis and pathological states (CDR score, MMSE z score, and global PiB deposition (SUVR)) of each subject are shown in Additional file 3
PiB Pittsburgh-compound B, SUVR standardized uptake value ratio, – or + PiB-PET positivity, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating,
ApoE apolipoprotein E, SEM standard error of mean, n number of subjects, N/M/D cognitively normal/mild impairment/dementia
aP value, significance by unpaired t-test except for clinical diagnosis, gender, and ApoE
bA revised value of the MMSE score with consideration for age, gender, and education level
†Pearson’s chi-square test
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ANOVA followed by Tukey’s multiple comparison test)
and had higher levels of MPP-Aβ42/40 (0.38 ± 0.01) than
both MCI+ (0.29 ± 0.02) and ADD+ (0.28 ± 0.01) sub-
jects (P < 0.001, Fig. 4a, right graph; ANOVA followed
by Tukey’s multiple comparison test). For further study,
we performed a bivariate correlation analysis to test the
relationship between MPP-Aβ level and global PiB de-
position (SUVR) indicating the degree of cortical Aβ
plaque deposition (Fig. 4b and Table 2) and compared
PiB– and PiB+ subjects (Fig. 4c). First, we performed the
Pearson’s correlation analysis for various groups. The
MPP-Aβ40 level and the MPP-Aβ42/40 ratio showed
significant correlation with global PiB deposition (SUVR)
(MPP-Aβ40, P < 0.0001, r = 0.23; MPP-Aβ42/40 ratio, P
< 0.0001, r = –0.23; Fig. 4b and Table 2) in the complete
study cohort (all, n = 353). Furthermore, there were sev-
eral significant correlations in many subgroups as well
as in the overall study group. Both MPP-Aβ42 (P < 0.01,
r = 0.3479) and MPP-Aβ40 (P < 0.01, r = 0.2950) levels
were dramatically correlated with global PiB deposition
Fig. 2 POC for the effects of MPP on Aβ quantification. a Gel electrophoresis for synthetic Aβ42 form assay. Twenty microliters of 8% DMSO in
1× PBS (–MPP) or 20 μl of 8% MPP solution in 1× PBS (+MPP) was added to 20 μl of 2 μM Aβ42 (final concentration, 1 μM; aliquots from the
same pool, in separate 1.5-ml tubes, n = 4), and the samples were electrophoresed. Band intensity squared deviation ((value – mean value)2)
indicates how far each point is from the mean value (**P < 0.01, F test to compare variances; each n = 4). b Gel electrophoresis for synthetic Aβ42
form assay with the original plasma sample. Twenty microliters of 8% DMSO and 25% plasma in 1× PBS (–MPP) or 20 μl of 8% MPP and 25%
plasma in 1× PBS (+MPP) was added to 20 μl of 2 μM Aβ42 (final concentration, 1 μM; aliquots from the same pool, in separate 1.5-ml tubes, n =
4), and the samples were electrophoresed. Band intensity squared deviation indicates how far each point is from the mean value (#P < 0.1, a trend
toward significance; **P < 0.01, F test to compare variances; each n = 4). c Repetitive measurement of synthetic Aβ42 (aliquots from the same
pool, in separate 1.5-ml tubes, n = 6) using xMAP technology, with or without MPP and/or HSA. HSA was used for mimicking blood plasma
condition. Squared deviation indicates how far each point is from the mean value (**P < 0.01 and ***P < 0.001, F test to compare
variances). d Repetitive measurement (aliquots from the same pooled plasma, in separate 1.5-ml tubes, n = 5) of plasma Aβ42 and Aβ40
using xMAP technology, with or without MPP. Squared deviation indicates how far each point is from the mean value (*P < 0.05 and **P < 0.01, F test
to compare variances). e Quantification of plasma Aβ42 and Aβ40 in a time-dependent manner using xMAP technology, with or without 4% MPP
solution in Bioplex sample diluent buffer (n= 4, independent individual plasma samples; *P< 0.05, unpaired t test for –MPP vs +MPP at each time point).
mmonomeric Aβ; o oligomeric Aβ, Aβ β-amyloid, MPP mixture of protease inhibitors and phosphatase inhibitors, HSA human serum albumin
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(SUVR) in MCI subjects (n = 79). The MPP-Aβ40 level
was significantly associated with global PiB deposition
(SUVR) in nondemented subjects (ND = CN plus
MCI, n = 294) (P < 0.001, r = 0.2177), in cognitively
impaired subjects (CI =MCI plus ADD, n =138) (P < 0.01,
r = 0.2272), and in CN subjects (n = 215) (P < 0.05, r =
0.1479) (Table 2). The MPP-Aβ42/40 ratio was correlated
with global PiB deposition (SUVR) in ND subjects (P <
0.01, r =–0.1654). Furthermore, the MPP-Aβ42/40 ratio
(P = 0.09, r = –0.1145) had a trend toward significant
correlation with global PiB deposition (SUVR) in CN
subjects (Table 2). This suggests that MPP-Aβ levels
reflect the state of Aβ plaque deposition in the brain.
Table 2 presents the detailed information of the cor-
relation between global PiB deposition (SUVR) and
MPP-Aβ levels. Next, we found that PiB– subjects
(CN– plus MCI– plus ADD–, n = 253) had signifi-
cantly different levels of MPP-Aβ40 (118.70 ± 2.09 pg/ml)
and MPP-Aβ42/40 ratio (0.36 ± 0.01) in comparison with
PiB+ subjects (CN+ plus MCI+ plus ADD+, n = 100; MPP-
Aβ40, 136.60 ± 3.37 pg/ml; MPP-Aβ42/40, 0.30 ± 0.01)
(Fig. 4c, P < 0.0001, unpaired t test). In addition, the MPP-
Aβ40 level and MPP-Aβ42/40 ratio were dramatically
different in PiB+ ND subjects (ND+, n = 57) (MPP-Aβ40,
134.80 ± 4.10 pg/ml; MPP-Aβ42/40, 0.31 ± 0.01) compared
with PiB– ND subjects (ND–, n = 237) (MPP-Aβ40,
117.80 ± 2.10 pg/ml; MPP-Aβ42/40, 0.36 ± 0.01)
(Fig. 4d, P < 0.01 and P < 0.0001, unpaired t test). Fur-
thermore, MCI+ subjects showed significantly higher
MPP-Aβ42 (39.46 ± 1.88 pg/ml) and MPP-Aβ40
(140.00 ± 6.86 pg/ml) levels than MCI– subjects
(MPP-Aβ42, 32.03 ± 1.37 pg/ml; MPP-Aβ40, 114.30 ±
6.86 pg/ml) (P < 0.01, Fig. 4a, left and middle graphs,
unpaired t test). Moreover, CN+ subjects showed signifi-
cantly lower values of MPP-Aβ42/40 ratio (0.33 ± 0.02)
than CN– subjects (0.39 ± 0.01) (P < 0.05, Fig. 4a, right
graph, unpaired t test) and higher values of MPP-
Aβ40 (129.40 ± 4.26 pg/ml) than CN– subjects
(118.80 ± 2.24 pg/ml) (P = 0.08, a trend toward signifi-
cance; Fig. 4a, middle graph, unpaired t test).
Prediction of cerebral amyloid deposition based on MPP-
Aβ42/40 ratio
To apply these analyzed results (Fig. 4) to practical use,
we performed a subsequent logistic regression and ROC
curve analysis using independent variables (Fig. 5). Mul-
tiple variables (MPP-Aβs and ApoE genotype) and con-
trol variables (gender and age) were mixed by logistic
Fig. 3 POC for the effect of MPP on distinction between subjects. a Intergroup differences in the plasma Aβ concentration with or without 4%
MPP solution using xMAP technology. MCI+ and ADD+ subjects show significantly decreased levels of MPP-Aβ42 and MPP-Aβ42/40 ratio compared with
CN– subjects (**P< 0.01 and ***P< 0.001 respectively; ANOVA followed by Tukey’s multiple comparison test; CN–, n= 20; MCI+, n= 12; ADD+, n= 23; total
subjects, n= 55). b Correlation of global PiB deposition (SUVR) and MPP-Aβs. MPP-Aβ42 level (***P< 0.001, r= –0.47; Pearson’s correlation) and MPP-Aβ42/
40 ratio (**P< 0.01, r= –0.39; Pearson’s correlation) are correlated with global PiB deposition (SUVR). Aβ β-amyloid, MPP mixture of protease inhibitors and
phosphatase inhibitors, MCI mild cognitive impairment, ADD Alzheimer’s disease dementia, CN cognitively normal, SUVR standard uptake value ratio, PiB
Pittsburgh compound B, – or + PiB negativity or positivity
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regression analysis, and the predicted probabilities were
used to assess the discrimination power (ROC curve
analysis) for the prediction of PiB-PET positivity. The
classification variable was ND– vs ND+ (Fig. 5a) or PiB– vs
PiB+ (Fig. 5b). The combination of MPP-Aβ42/40 and
control variables (gender and age) increased the area
under curve (AUC) values (ND– vs ND+, 0.695; PiB– vs
PiB+, 0.682) compared with MPP-Aβ42/40 alone (ND– vs
ND+, 0.639; PiB– vs PiB+, 0.668) (Fig. 5 and Table 3).
Furthermore, AUC values were further enhanced on adding
the ApoE variable (ND– vs ND+, 0.783; PiB– vs PiB+,
0.799). Table 3 presents more detail about the results of
logistic regression followed by ROC curve analysis.
Discussion
Plasma Aβ levels are believed unstable, and many
plasma proteins such as HSA, TTR, and others are
believed to interrupt the detection of Aβ [24, 26]. Fur-
thermore, the plasma contains diverse proteases released
from neutrophils and phagocytes [40, 47, 48]. Although
the plasma contains several protease inhibitors such as
α2-macroglobulin, α1-protease inhibitor, and plasmino-
gen activator inhibitor-1 (PAI-1) [49–52], these are not
sufficient for the preservation of the integrity of plasma
proteins during the storage of samples at 4 °C or RT
[53]. Moreover, Kumar et al. [31] reported that phos-
phorylation of Aβ at Ser-8 inhibited the degradation of
monomeric Aβ. Accurate analysis with plasma requires a
high quality of starting samples; however, there have
been no previous attempts to stabilize the plasma Aβ by
chemical treatment. We hypothesized that protease
inhibitors and phosphatase inhibitors might have a role
in reducing Aβ degradation because the Aβ sequence
contains many possible proteases and phosphorylation
sites [30, 31]. We found that the variation in Aβ concen-
tration through repetitive measurement (using western
blot and Luminex system) was significantly reduced by
MPP treatment in a variety of settings including Aβ with
pure sample diluent buffer (1× PBS or Bioplex buffer)
Fig. 4 MPP-Aβs reflect the pathological load of Aβ in the brain. a
Intergroup differences of MPP-Aβ levels using xMAP technology
(*P < 0.05 and **P < 0.01, unpaired t test; §P < 0.05, §§P < 0.01, and
§§§P < 0.001, ANOVA followed by Tukey’s multiple comparison
test; #P< 0.10, unpaired t test, trend toward significance; CN–, n= 187,
CN+, n= 28, MCI–, n= 50, MCI+, n= 29, ADD–, n= 16, ADD+, n= 43;
total subjects n= 353). b Correlation of global PiB deposition (SUVR) and
MPP-Aβs (n= 353, ***P< 0.0001; Pearson’s correlation). c, d MPP-Aβ42,
MPP-Aβ40, and MPP-Aβ42/40 levels in ND– (n = 237; CN– and
MCI–), ND+ (n = 57; CN+ and MCI+), PiB– (n = 253; CN–, MCI–,
and ADD–), and PiB+ (n= 100; CN+, MCI+, and ADD+) (**P< 0.01, and
***P< 0.001, unpaired t test). Aβ β-amyloid, MPPmixture of protease
inhibitors and phosphatase inhibitors, MCI mild cognitive impairment,
ADD Alzheimer’s disease dementia, CN cognitively normal, SUVR standard
uptake value ratio, PiB Pittsburgh compound B, – or + PiB negativity or
positivity, ND nondemented
Table 2 Detailed information of the correlation between brain amyloid deposition (global PiB deposition (SUVR)) and MPP-Aβs
CN MCI ADD ND CI PiB– PiB+ All
(n = 215) (n = 79) (n = 59) (n = 294) (n = 138) (n = 253) (n = 100) (n = 353)
MPP-Aβ42 P = 0.7982 **P < 0.01 P = 0.3132 P = 0.9827 P = 0.1125 P = 0.9750 P = 0.7965 P = 0.1776
r = 0.0175 r = 0.3479 r = –0.1336 r = –0.0012 r = 0.1357 r = 0.0020 r = –0.0261 r = –0.0719
MPP-Aβ40 *P = 0.0301 **P < 0.01 P = 0.6639 ***P < 0.001 **P < 0.01 P = 0.8155 P = 0.2436 ****P < 0.0001
r = 0.1479 r = 0.2950 r = 0.0578 r = 0.2177 r = 0.2272 r = –0.0147 r = 0.1177 r = 0.2309
MPP-Aβ42/40 #P = 0.0940 P = 0.6395 P = 0.2868 **P < 0.01 P = 0.6488 P = 0.7416 P = 0.4437 ****P < 0.0001
r = –0.1145 r = 0.0535 r = –0.1410 r = –0.1654 r = –0.0391 r = –0.0208 r = –0.0775 r = –0.2280
SUVR standard uptake value ratio, MPP-AβMPP-treated plasma β-amyloid, CN cognitively normal, MCImild cognitive impairment, ADD Alzheimer’s disease dementia, ND
nondemented group (CN plus MCI), CI cognitively impaired group (MCI plus ADD), PiB– or PiB+ subjects with negative or positive amyloid deposition, All
complete study cohort
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 and Pearson r values by Pearson’s correlation analysis (two-tailed)
#P < 0.10, trend toward significance
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(Fig. 2a, c), with plasma mimic buffer using HSA (Fig. 2c)
[43], and with diluent buffer containing the original
plasma sample (Fig. 2b, d). The purpose of repetitively
measuring experiments (Fig. 2a–d) was to investigate
whether the same samples distributed in different tubes
show the same concentration value. Because of the in-
stability of Aβ peptides, the detected values might have
changed (during the incubation for 30 min at RT)
depending on the independent tubes, even though they
were same samples. As expected, without MPP treat-
ment, the detected values fluctuated; however, when we
treated samples with MPP, the detected values were
quite similar to each other. This indicates that MPP
allows us to control the unavoidable experimental errors
(especially unexpected time delay) that occur during the
experiment procedure. Furthermore MPP-treated
plasma Aβ42 and Aβ40 (MPP-Aβ42 and MPP-Aβ40)
maintained their concentration efficiently for 24 h
whereas non-MPP-treated plasma Aβ42 (nMPP-Aβ42)
levels decreased rapidly, and nMPP-Aβ40 levels fluctu-
ated with incubation times (Fig. 2e). These results indi-
cate that MPP might have a stabilizing effect on the
quantification of plasma Aβs. Hence, we next differenti-
ated PiB– (CN–, MCI–, and ADD–) vs PiB+ (CN+, MCI
+, and ADD+) subjects using MPP-Aβs. Interestingly,
although not all comparisons were statistically signifi-
cant, most cases comparing PiB– vs PiB+ had the same
patterns for MPP-Aβ40 level and MPP-Aβ42/40 ratio
(MPP-Aβ40, CN– < CN+, MCI– <MCI+, and ADD– <
ADD+; MPP-Aβ42/40, CN– > CN+, and ADD– >
ADD+; Fig. 4a). Hence, we compared the subjects
again as ND– vs ND+ and PiB– vs PiB+. The MPP-
Aβ40 level was dramatically increased, and the
MPP-Aβ42/40 ratio was significantly reduced in ND+ and
PiB+ in comparison with ND– and PiB– subjects respect-
ively (Fig. 4c, d). This indicates that MPP-Aβ might be a
Fig. 5 Logistic regression model and ROC curve analysis for PiB-PET prescreening ROC curve model using a combination of variables (MPP-Aβs,
gender, age, and ApoE types) following the logistic regression analysis comparing (a) ND– and ND+ or (b) PiB– and PiB+. See details in Table 3.
PiB Pittsburgh compound B, – or + PiB negativity or positivity, ND nondemented, ApoE apolipoprotein E, MPP-Aβ MPP-treated plasma β-amyloid,
AUC area under curve
Table 3 Detailed information of ROC curve analysis
Panel AUC Sensitivity (%) Specificity (%) P value Cutoff criterion 95% CI of AUC
ND– vs ND+
MPP-Aβ42/40 0.639 71.8 51.5 <0.0001 >0.1871 0.559–0.719
MPP-Aβ42/40 + age + gender 0.695 79.0 57.8 <0.0001 >0.1864 0.622–0.767
MPP-Aβ42/40 + age + gender + ApoE 0.783 80.7 69.2 <0.0001 >0.1730 0.715–0.852
PiB– vs PiB+
MPP-Aβ42/40 0.668 71.0 52.2 <0.0001 >0.2731 0.605–0.731
MPP-Aβ42/40 + age + gender 0.682 71.0 54.2 <0.0001 >0.2759 0.622–0.741
MPP-Aβ42/40 + age + gender + ApoE 0.799 78.0 66.8 <0.0001 >0.2230 0.746–0.852
ApoE Apolipoprotein E, AUC area under curve, MPP mixture of protease inhibitors and phosphatase inhibitors, CI confidence interval, ROC receiver operating
characteristic, – or + PiB-PET positivity, ND– PiB-PET-negative cognitively normal (CN) and PiB-PET-negative subjects with mild cognitive impairment (MCI), ND+
PiB-PET-positive CN and PiB-PET-positive MCI, PiB– grouped CN–, MCI–, and ADD–, PiB+ grouped CN+, MCI+, and ADD+
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potential biomarker to predict Aβ deposition in the brain.
Although the age of subjects who were PiB+ was relatively
higher than that of PiB– subjects (Table 1), the significant
difference of MPP-Aβs between PiB+ and PiB– subjects
(MPP-Aβ40 increased and MPP-Aβ42/40 decreased in
PiB+, compared with PiB–; Fig. 4c) was not due to
the effects of aging because comparing young-middle-
aged controls (YC, cognitively normal subjects with
age 20–55 years, n = 61) vs CN– subjects showed
completely opposite trends to PiB– vs PiB+ subjects,
regarding MPP-Aβs (see Additional files 5 and 6 for
more detail).
Even in cases where the MPP-Aβ42/40 ratio was
dramatically different between PiB– and PiB+ subjects,
it was insufficient to be used as a variable for ROC curve
analysis to discriminate ND– vs ND+ or PiB– vs PiB+
subjects (ND– vs ND+, AUC 0.639 with 71.8% sensitivity
and 51.5% specificity; PiB– vs PiB+, AUC 0.668 with 71.0%
sensitivity and 52.2% specificity; Fig. 5 and Table 3). Using
the combination of additional risk factors (gender, age, and
ApoE types) reported previously [54, 55], we conducted the
logistic regression analysis followed by ROC curve analysis
to establish the screening model for cerebral amyloid
deposition. We showed that the combination of MPP-
Aβ42/40 ratio, gender, and age had a stronger dis-
crimination power (ND– vs ND+, AUC 0.695 with
79.0% sensitivity and 57.8% specificity; PiB– vs PiB+,
AUC 0.682 with 71.0% sensitivity and 54.2% specifi-
city; Fig. 5 and Table 3) than the MPP-Aβ42/40 level
alone. Furthermore, we observed that AUC was
increased further by ApoE variable (ND– vs ND+,
AUC 0.783 with 80.7% sensitivity and 69.2% specificity;
PiB– vs PiB+, AUC 0.799 with 78.0% sensitivity and 66.8%
specificity; Fig. 5 and Table 3).
These results are in line with several previous reports
that showed an interrelationship between plasma Aβ42/
40 ratio and dementia [56, 57]. However, this study is
the first to stabilize the quantification of plasma Aβ by
the treatment of chemicals and predict the PiB-PET
positivity by classifying the subjects into two large
groups, ND– vs ND+ subjects and PiB– vs PiB+ sub-
jects, regardless of the stage of cognitive impairment.
We showed a distinct relationship between MPP-Aβs
and pathological AD-related Aβ burden in the brain. In
conclusion, these results suggest that our model using
MPP-Aβs and other factors could be utilized as a pre-
screening tool to predict cerebral Aβ deposition.
Conclusions
The treatment of the plasma with a mixture of protease
inhibitors and phosphatase inhibitors (MPP) provides an
improved detection method for reliable plasma Aβ level,
and MPP-Aβs showed a correlation with Aβ burden in
the brain.
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significantly higher MPP-Aβ42 and MPP-Aβ42/40 ratio than YC (***P< 0.001,
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